胆汁淤积的定义、病因及分类
汪佩文, 董育玮 . 胆汁淤积的定义、病因及分类[J]. 内科理论与实践, 2022 , 17(01) : 15 -23 . DOI: 10.16138/j.1673-6087.2022.01.004
| [1] | Kuntz K, Kuntz HD. Hepatology: principles and practice[M]. 2nd ed. Heidelberg: Springer Medizin Verlag, 2006:227-242. |
| [2] | Wu H, Chen C, Ziani S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10(5): 1107. |
| [3] | 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015)[J]. 中华肝脏病杂志, 2015: 23(12): 924-933. |
| [4] | Sherlock S, Dooley J. Cholestasis//Sherlock S, Dooley J ed. Disease of the liver and biliary system[M]. 11th ed. United Kingdom: Blackwell Publishing, 2002: 219-240. |
| [5] | 王宝恩, 尹姗姗. 胆汁淤积及胆汁淤积性疾病[C]. 全国肝脏疾病学术研讨会, 2003: 6-16. |
| [6] | 胆汁淤积性肝病诊断治疗专家委员会. 胆汁淤积性肝病诊断治疗专家共识[J]. 中华肝脏病杂志, 2009: 1(2): 34-35. |
| [7] | 陈小青, 王迎春. 肝内胆汁淤积性肝病的病因与治疗[J]. 实用肝脏病杂志, 2018, 21(2): 163-165. |
| [8] | European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267. |
| [9] | Burt A, Portmann B, Ferrell L. MacSween’s pathology of the liver[M]. 6th ed. Elsevier, 2012: 503-562. |
| [10] | Lefkowitch JH. Scheuer’s liver biopsy interpretation[M]. 9th ed. Elsevier, 2016: 53. |
| [11] | Hilscher MB, Kamath PS, Eaton JE. Cholestatic liver diseases[J]. Mayo Clin Proc, 2020, 95(10): 2263-2279. |
| [12] | 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 中华内科杂志, 2021, 60(12): 1075-1087. |
| [13] | Wang K. Molecular mechanisms of liver injury: apoptosis or necrosis[J]. Exp Toxicol Pathol, 2014, 66(8): 351-356. |
| [14] | Jayappa M, Kumar P, Goyal JP. Prolonged cholestasis after acute viral hepatitis: successfully treated with oral steroid[J]. BMJ Case Rep, 2020, 13(5): e234430. |
| [15] | Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A[J]. Cold Spring Harb Perspect Med, 2018, 8(9): a031708. |
| [16] | 沈斐斐, 陆伦根. 胆汁淤积性肝病的病因[J]. 实用肝脏病杂志, 2016, 19(6): 644-646. |
| [17] | Hao H, Cao L, Jiang C, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis[J]. Cell Metab, 2017, 25(4): 856-867. |
| [18] | Bhogal HK, Sanyal AJ. The molecular pathogenesis of cholestasis in sepsis[J]. Front Biosci(Elite Ed), 2013, E5(1): 87-96. |
| [19] | Sorrentino P, Tarantino G, Perrella A, et al. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2005, 50(6): 1130-1135. |
| [20] | Jüngst C, Berg T, Cheng J, et al. Intrahepatic cholestasis in common chronic liver diseases[J]. Eur J Clin Invest, 2013, 43(10): 1069-1083. |
| [21] | 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11): 810-820. |
| [22] | Chatterjee S, Annaert P. Drug-induced cholestasis: mechanisms, models, and markers[J]. Curr Drug Metab, 2018, 19(10): 808-818. |
| [23] | Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966. |
| [24] | Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury[J]. Gastroenterology, 2015, 148(7): 1340-1352. |
| [25] | Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease[J]. Gut, 1999, 44(5): 731-735. |
| [26] | 杨婉娜, 谢雯. 药物性肝损伤的临床表现和分型[J]. 临床肝胆病杂志, 2021, 37(11): 2525-2529. |
| [27] | Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors[J]. Hepatology, 2020, 72(1): 315-329. |
| [28] | Schatz SB, Jüngst C, Keitel-Anselmo V, et al. Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset[J]. Hepatol Commun, 2018, 2(5): 504-514. |
| [29] | Delaunay JL, Durand-Schneider AM, Delautier D, et al. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature[J]. Hepatology, 2009, 49(4): 1218-1227. |
| [30] | Cabrerizo R, Castaño GO, Burgueño AL, et al. Promoter DNA methylation of farnesoid X receptor and pregnane X receptor modulates the intrahepatic cholestasis of pregnancy phenotype[J]. PLoS One, 2014, 9(1): e87697. |
| [31] | Massafra V, Pellicciari R, Gioiello A, et al. Progress and challenges of selective Farnesoid X Receptor modulation[J]. Pharmacol Ther, 2018, 191: 162-177. |
| [32] | Song Z, Shi Q. The interaction of PPARα and CYP7B1 with ERα, β impacted the occurrence and development of intrahepatic cholestasis in pregnant rats[J]. Reprod Sci, 2017, 24(4): 627-634. |
| [33] | Song X, Vasilenko A, Chen Y, et al. Transcriptional dynamics of bile salt export pump during pregnancy: mechanisms and implications in intrahepatic cholestasis of pregnancy[J]. Hepatology, 2014, 60(6): 1993-2007. |
| [34] | Wei W, Hu YY. Expression of hypoxia-regulated genes and glycometabolic genes in placenta from patients with intrahepatic cholestasis of pregnancy[J]. Placenta, 2014, 35(9): 732-736. |
| [35] | Reyes H, Báez ME, González MC, et al. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile[J]. J Hepatol, 2000, 32(4): 542-549. |
| [36] | Mitra A, Ahn J. Liver disease in patients on total parenteral nutrition[J]. Clin Liver Dis, 2017, 21(4):687-695. |
| [37] | Krebs-Schmitt D, Briem-Richter A, Brinkert F, et al. Alloimmunity and cholestasis after liver transplantation in children with progressive familial intrahepatic cholestasis[J]. J Pediatr Gastroenterol Nutr, 2019, 68(2): 169-174. |
| [38] | Amirneni S, Haep N, Gad MA, et al. Molecular overview of progressive familial intrahepatic cholestasis[J]. World J Gastroenterol, 2020, 26(47): 7470-7484. |
| [39] | 董育玮, 李郑红, 汪佩文, 等. 良性复发性肝内胆汁淤积伴先天性黄疸一例报道[J]. 诊断学理论与实践, 2017, 16(4): 434-436. |
| [40] | 唐诚芳, 冯毅, 徐伟, 等. 广州市Citrin缺乏症新生儿筛查及 SLC25A13基因变异分子流行病学特征[J]. 中华实用儿科临床杂志, 2020, 35(11): 838-841. |
| [41] | 宋元宗. Citrin缺陷导致的新生儿肝内胆汁淤积症发病机制和治疗策略:聚焦胆小管膜载体蛋白[J]. 中华实用儿科临床杂志, 2018, 33(19): 1447-1450. |
| [42] | 卢致琨, 刘丽, 李端, 等. Citrin蛋白缺陷所致新生儿肝内胆汁淤积症患儿SLC25A13基因突变分析[J]. 中华实用儿科临床杂志, 2018, 33(8): 615-617. |
| [43] | Abuduxikuer K, Chen R, Wang ZL, et al. Risk factors associated with mortality in neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) and clinical implications[J]. BMC Pediatr, 2019, 19(1): 18. |
| [44] | Alagille D, Odièvre M, Gautier M, et al. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur[J]. J Pediatr, 1975, 86(1): 63-71. |
| [45] | Warthen DM, Moore EC, Kamath BM, et al. Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate[J]. Hum Mutat, 2006, 27(5): 436-443. |
| [46] | 王建设. Alagille综合征[J]. 中国实用儿科杂志, 2008, 23(1): 3-6. |
| [47] | 郭丽, 宋元宗. Alagille综合征患儿临床治疗管理[J]. 实用肝脏病杂志, 2021, 24(2): 160-163. |
| [48] | Mutlu M, Aslan Y, Aktürk-Acar F, et al. ARC syndrome[J]. Turk J Pediatr, 2017, 59(4): 487-490. |
| [49] | Cullinane AR, Straatman-Iwanowska A, Zaucker A, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization[J]. Nat Genet, 2010, 42(4): 303-312. |
| [50] | Zhou Y, Zhang J. Arthrogryposis-renal dysfunction-cholestasis(ARC) syndrome: from molecular genetics to clinical features[J]. Ital J Pediatr, 2014, 40: 77. |
| [51] | Wang JS, Zhao J, Li LT. ARC syndrome with high GGT cholestasis caused by VPS33B mutations[J]. World J Gastroenterol, 2014, 20(16): 4830-4834. |
| [52] | Chinnery PF, DiMauro S. Mitochondrial hepatopathies[J]. J Hepatol, 2005, 43(2): 207-209. |
| [53] | 张志华, 马雪萍, 郭红梅. TRMU基因突变致线粒体肝病一例[J]. 中华儿科杂志, 2020, 58(7): 602-604. |
| [54] | 中华人民共和国国家卫生健康委员会. 先天性胆汁酸合成障碍诊治指南[J]. 中国实用乡村医生杂志, 2019, 26(9): 12-13. |
| [55] | 代东伶. 先天性胆汁酸合成障碍[J]. 临床儿科杂志, 2015, 33(4): 301-305. |
| [56] | Tanaka A, Leung PSC, Gershwin ME. Evolution of our understanding of PBC[J]. Best Pract Res Clin Gastroenterol, 2018, 34-35: 3-9. |
| [57] | Chuang YH, Lian ZX, Cheng CM, et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives[J]. J Autoimmun, 2005, 25(2): 126e32. |
| [58] | Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis—a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. |
| [59] | De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face[J]. Acta Paediatr, 2020, 109(5): 893-899. |
| [60] | McDonald GB. Hepatobiliary complications of hemato-poietic cell transplantation, 40 years on[J]. Hepatology, 2010, 51(4): 1450-1460. |
/
| 〈 |
|
〉 |
